These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 2118787)
21. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. Snider DE; Caras GJ; Koplan JP JAMA; 1986 Mar; 255(12):1579-83. PubMed ID: 3081740 [TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. de Perio MA; Tsevat J; Roselle GA; Kralovic SM; Eckman MH Arch Intern Med; 2009 Jan; 169(2):179-87. PubMed ID: 19171815 [TBL] [Abstract][Full Text] [Related]
23. Tuberculosis prevention in methadone maintenance clinics. Effectiveness and cost-effectiveness. Snyder DC; Paz EA; Mohle-Boetani JC; Fallstad R; Black RL; Chin DP Am J Respir Crit Care Med; 1999 Jul; 160(1):178-85. PubMed ID: 10390397 [TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening. Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045 [TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness analysis of school based Mantoux screening for TB infection. Lowin A; Slater J; Hall J; Alperstein G Aust N Z J Public Health; 2000 Jun; 24(3):247-53. PubMed ID: 10937400 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of alternative strategies for interferon-γ release assays and tuberculin skin test in tuberculous uveitis. Ang M; Nguyen HV; Kiew SY; Chen S; Chee SP; Finkelstein E Br J Ophthalmol; 2015 Jul; 99(7):984-9. PubMed ID: 25573149 [TBL] [Abstract][Full Text] [Related]
27. Screening for proteinuria in US adults: a cost-effectiveness analysis. Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Deuffic-Burban S; Atsou K; Viget N; Melliez H; Bouvet E; Yazdanpanah Y Int J Tuberc Lung Dis; 2010 Apr; 14(4):471-81. PubMed ID: 20202306 [TBL] [Abstract][Full Text] [Related]
29. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors. Rose DN; Schechter CB; Silver AL JAMA; 1986 Nov; 256(19):2709-13. PubMed ID: 3773178 [TBL] [Abstract][Full Text] [Related]
30. Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant. Wong G; Li MW; Howard K; Hua DK; Chapman JR; Bourke M; Turner R; Tong A; Craig JC Nephrol Dial Transplant; 2013 Apr; 28(4):917-26. PubMed ID: 23182812 [TBL] [Abstract][Full Text] [Related]
31. Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis. Tan M; Menzies D; Schwartzman K BMC Public Health; 2008 Jun; 8():201. PubMed ID: 18534007 [TBL] [Abstract][Full Text] [Related]
32. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands. Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ; Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965 [TBL] [Abstract][Full Text] [Related]
33. A risk/cost analysis of alternative screening intervals for occupational tuberculosis infection. Nicas M Am Ind Hyg Assoc J; 1998 Feb; 59(2):104-12. PubMed ID: 9487664 [TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of screening immigrants for hepatitis B. Wong WW; Woo G; Jenny Heathcote E; Krahn M Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300 [TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness of high resolution computed tomography with interferon-gamma release assay for tuberculosis contact investigation. Kowada A Eur J Radiol; 2013 Aug; 82(8):1353-8. PubMed ID: 23489981 [TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range? Anderson R; Haas M; Shanahan M Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013 [TBL] [Abstract][Full Text] [Related]
38. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. Jordan TJ; Lewit EM; Montgomery RL; Reichman LB JAMA; 1991 Jun; 265(22):2987-91. PubMed ID: 2033771 [TBL] [Abstract][Full Text] [Related]
39. Optimal screening strategy for familial intracranial aneurysms: a cost-effectiveness analysis. Bor AS; Koffijberg H; Wermer MJ; Rinkel GJ Neurology; 2010 May; 74(21):1671-9. PubMed ID: 20498435 [TBL] [Abstract][Full Text] [Related]
40. Community-based tuberculin screening in Montreal: a cost-outcome description. Adhikari N; Menzies R Am J Public Health; 1995 Jun; 85(6):786-90. PubMed ID: 7762710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]